IKBKB and neoplasm: In the PDG glioma mouse model, IRF/IKKβ NP treatments suppressed the tumor progression following intravenous infusion of nine doses (three doses/week for three weeks), and significant tumor inhibition was obtained when combining the nanoparticles treatment with the standard-of-care radiotherapy (Figure 3).